9 completed, 6 terminated, 1 withdrawn. 16 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 9, Terminated 6, Withdrawn 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Stage IIIC Melanoma: new trials by email Literature Review of Stage IIIC Melanoma trials Research Report on Stage IIIC Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations trametinib, laboratory biomarker analysis, pharmacological study - Recurrent Melanoma, Stage IIIB Melanoma | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 9 | 2015-01-01 | 2021-05-28 |
| High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery aldesleukin, ipilimumab, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | CINJRegulatory | 9 | 2014-11-26 | 2023-07-18 |
| Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic cytology specimen collection procedure, MEK 162 therapy or molecularly targeted therapy, therapeutic procedure - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Completed | Yale University | 49 | 2014-05-01 | 2020-01-02 |
| Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery dabrafenib, trametinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced) | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 13 | 2013-01-01 | 2017-06-23 |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib Akt inhibitor MK2206, selumetinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2012-01-01 | 2014-06-18 |
| Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery axitinib, laboratory biomarker analysis - Extraocular Extension Melanoma, Metastatic Intraocular Melanoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 25 | 2012-01-01 | 2018-05-09 |
| Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma therapeutic conventional surgery, laboratory biomarker analysis, Axitinib - Melanoma, Malignant Melanoma | Phase 2 | Completed | University of California, Irvine | 11 | 2011-12-01 | 2021-01-20 |
| Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma laboratory biomarker identification and analysis, biopsy, immunohistochemistry/tissue microarrays - Recurrent Melanoma, Stage IIIc Melanoma | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 12 | 2011-10-01 | 2016-05-30 |
| RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery gamma-secretase/Notch signalling pathway inhibitor RO4929097, pharmacological study, therapeutic conventional surgery - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2010-09-01 | 2013-01-31 | |
| Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma Denileukin diftitox - Stage IIIC Melanoma, Stage IV Melanoma | Phase 2 | Completed | Eisai Inc. | 75 | 2010-06-22 | 2022-04-13 |
| Dinaciclib in Treating Patients With Stage III-IV Melanoma dinaciclib, pharmacological study, laboratory biomarker analysis - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 12 | 2009-09-01 | 2017-04-04 |
| Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery imatinib mesylate, laboratory biomarker analysis - Acral Lentiginous Malignant Melanoma, Recurrent Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2007-04-01 | 2014-12-23 |
| Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma dasatinib - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 39 | 2006-12-01 | 2014-05-15 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma tyrosinase peptide, gp100 antigen, MART-1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2004-06-01 | 2015-04-15 |
| Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | University of Southern California | 42 | 2004-05-01 | 2014-05-22 |
| Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma HPV 16 E7:12-20, gp100:209-217(210M), laboratory biomarker analysis - Recurrent Melanoma, Stage IA Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 1999-04-01 | 2017-02-20 |
Melanoma (16) · Uveal Melanoma (3) · Neoplasms (1)
Neoplasms by Histologic Type (16) · Neoplasms by Site (16) · Neoplasms, Germ Cell and Embryonal (16) · Neoplasms, Nerve Tissue (16) · Neuroectodermal Tumors (16) · Neuroendocrine Tumors (16) · Nevi and Melanomas (16) · Skin Diseases (16) · Skin Neoplasms (16) · Skin and Connective Tissue Diseases (16) · Neoplasms (15) · Eye Diseases (3) · Eye Neoplasms (3) · Uveal Diseases (3) · Uveal Neoplasms (3)
Axitinib (2) · incomplete Freund's adjuvant (2) · montanide ISA 51 (2) · trametinib (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · AZD 6244 (1) · Biopsy (1) · CTLA-4 Antigen (1) · Coal Tar (1) · Dasatinib (1) · Imatinib Mesylate (1) · Immunohistochemistry (1) · Interleukin-2 (1) · Ipilimumab (1) · MAGEA3 protein, human (1)
National Cancer Institute (NCI) (7) · Vanderbilt-Ingram Cancer Center (3) · CINJRegulatory (1) · Eisai Inc. (1) · Roswell Park Cancer Institute (1) · University of California, Irvine (1) · University of Southern California (1) · Yale University (1)
United States (16)
Jeffrey Weber (2) · Anna Pavlick (1) · Douglas Johnson (1) · Frank Hodi (1) · Harriet Kluger (1) · Howard Kaufman (1) · Jeffrey Sosman (1) · Jeffrey Sosman, MD (1) · John P. Fruehauf, MD, PhD (1) · Mark Kelley (1) · Matuesz Opyrchal, MD (1) · Patricia LoRusso, D.O. (1) · Richard Carvajal (1) · Walter J. Urba, MD, PhD (1)
PMID 21642685, PMID 25797743, PMID 31998643, PMID 33861486
N01CM62204 (2), N01CM00100 (1), N01CM62206 (1), P30CA006516 (1), P30CA008748 (1), P30CA016056 (1), P30CA016359 (1), P30CA022453 (1), P30CA068485 (1), P30CA072720 (1), R21CA082614 (1), U01CA062490 (1)